Английская Википедия:Delix Therapeutics
Delix Therapeutics is an American biotech company based in Boston, Massachusetts.[1] The company develops novel neuroplasticity-promoting therapeutics for central nervous system (CNS) diseases such as depression and post-traumatic stress disorder (PTSD).[2] It was co-founded in 2019 by David E. Olson and Nick Haft.[3]
Company History
The company was founded to develop novel, non-hallucinogenic psychoplastogens, also known as neuroplastogens, to better treat mental health disorders at scale. David E. Olson founded the company following his discovery that psychedelics are highly potent neuroplasticity-promoting compounds.[2] In September 2021, Delix secured a Series A financing round, the largest in the space, to continue their work focused on neuroplastogens and neuroplasticity therapeutics.[4] Also in Fall of 2021, Delix joined the National Institute on Drug Abuse industry partnering program to screen psychoplastogens in models of substance use disorder.[2] In 2021, the company expanded the leadership team, adding a new CEO,[5] CSO,[1] and CMO[1]
Awards
In 2021, Delix was named one of the Fierce 15 of Biotech.[6] In 2022, Nature named Delix Spinout of the Year[7] and Delix was awarded the Healthcare Businesswomen's Association (HBA) ACE award.[8] In 2023, Delix was a finalist for the Prix Galien award for Best Startup[9] and the BWB award for Biotech Innovation of the Year[10] and won the Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year.[11]
Product Candidates
To date, the company has synthesized over 2000 novel psychoplastogens.[12] Many of these small molecule compounds are analogs of known psychedelics such as ibogaine and 5-MeO-DMT.[13] Delix focuses on the development of non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.[14] Their compounds have been engineered to lack cardiotoxicity and psychostimulant properties characteristic of other first-generation psychoplastogens.[15] Two of the company’s known scaffolds are tabernanthalog and AAZ-A-154.[16] Delix has licensed these compounds from UC Davis.[17]
See also
References
- ↑ 1,0 1,1 1,2 Шаблон:Cite web
- ↑ 2,0 2,1 2,2 Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite magazine
- ↑ Шаблон:Cite web
- ↑ https://www.fiercebiotech.com/special-report/fierce-biotech-s-2021-fierce-15-0
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite press release
- ↑ Шаблон:Cite press release
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite magazine
- ↑ Шаблон:Cite journal
- Английская Википедия
- Biopharmaceutical companies
- Pharmaceutical companies of the United States
- Biotechnology companies established in the 21st century
- Biotechnology companies of the United States
- Companies based in Boston
- American companies established in 2019
- 2019 establishments in Massachusetts
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии
